LGVN Longeveron Inc.
$1.61▲ +0.31%
Healthcare
Other
Volume 91.0K
Avg Volume (10D) 85.3K
Key Metrics & Fundamentals
Market Cap
$5.12M
P/E Ratio
–
Div Yield
0.00%
52W Range
1.31 - 12.30
% vs 50 MA
-63.62%
% vs 200 MA
-76.10%
RSI-14
27.5
MACD Histogram
+0.1100
Beta (1Y vs SPY)
0.59
Free Cash Flow
-$5.76M
Gross Rev
$287,000
Gross Profit
$182,000
EBITDA
-$5.95M
COGS
$105,000
Operating Exp
$6.35M
Operating Income
-$6.17M
EBIT
-$6.17M
Pretax Income
-$6.07M
Net Income
-$6.07M
EPS (Diluted)
-0.19
Price & Volume History
Loading chart…
Recent News
Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
GlobeNewswire · Oct 26, 2026 9:15 AM ET
Longeveron to Participate in Three Longevity/Aging Investment Conferences
GlobeNewswire · Sep 30, 2026 4:05 PM ET
Longeveron (LGVN) Heart Treatment Falls Short. Can a Strategic Review Preserve Value?
Insider Monkey · Sep 22, 2026 7:54 PM ET
Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug
BioPharma Dive · Sep 18, 2026 6:24 AM ET
Top Midday Decliners
MT Newswires · Sep 17, 2026 2:36 PM ET
LGVN Posts Disappointing Trial Results
Zacks Small Cap Research · Sep 17, 2026 7:14 AM ET
Longeveron Shares Halted After Heart Therapy Trial Misses Primary Endpoint
MT Newswires · Sep 16, 2026 6:07 PM ET
Longeveron Announces Topline Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
GlobeNewswire · Sep 16, 2026 5:27 PM ET
Longeveron to Present at the H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire · Sep 3, 2026 9:15 AM ET
Longeveron Announces 1-for-10 Reverse Stock Split
MT Newswires · Aug 24, 2026 4:30 PM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See LGVN's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.